Filing Details

Accession Number:
0000899243-19-003700
Form Type:
5
Zero Holdings:
No
Publication Time:
2019-02-14 18:24:07
Reporting Period:
2018-12-31
Accepted Time:
2019-02-14 18:24:07
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1731831 Eidos Therapeutics Inc. EIDX () 5
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1621788 J. Ali Satvat C/O Eidos Therapeutics, Inc.
101 Montgomery Street, Suite 2550
San Francisco CA 94104
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-12-03 1,750,000 $15.50 21,364,655 No 4 P Indirect See footnote
Common Stock Acquisiton 2018-12-05 1,103,848 $14.01 22,468,503 No 4 P Indirect See footnote
Common Stock Acquisiton 2018-12-06 38,970 $13.34 22,507,473 No 4 P Indirect See footnote
Common Stock Acquisiton 2018-12-07 36,314 $13.94 22,543,787 No 4 P Indirect See footnote
Common Stock Acquisiton 2018-12-07 4,860 $14.36 22,548,647 No 4 P Indirect See footnote
Common Stock Acquisiton 2018-12-10 37,989 $13.29 22,586,636 No 4 P Indirect See footnote
Common Stock Acquisiton 2018-12-10 2,664 $13.96 22,589,300 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See footnote
No 4 P Indirect See footnote
No 4 P Indirect See footnote
No 4 P Indirect See footnote
No 4 P Indirect See footnote
No 4 P Indirect See footnote
No 4 P Indirect See footnote
Footnotes
  1. The shares are owned by BridgeBio Pharma LLC. The Reporting Person is a member of the board of managers of BridgeBio Pharma LLC and may be deemed to beneficially own the shares held by BridgeBio Pharma LLC. The Reporting Person disclaims beneficial ownership of the shares for Section 16 purposes or for any other purpose, except to the extent of his pecuniary interest therein.
  2. Represents the weighted average purchase price of the shares purchased ranging from $12.79 to $13.55 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
  3. Represents the weighted average purchase price of the shares purchased ranging from $13.33 to $14.32 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
  4. Represents the weighted average purchase price of the shares purchased ranging from $13.34 to $14.48 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
  5. Represents the weighted average purchase price of the shares purchased ranging from $12.85 to $13.84 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
  6. Represents the weighted average purchase price of the shares purchased ranging from $13.86 to $14.00 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.